RVTYRevvity Inc.
$104.09
$2.35
(2.21%)
Pre-Market
EarningsAug 4
Mkt Cap$11.87B
Vol1,014.00
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
Revvity, Inc. (NYSE: RVTY) today published its 2026 Impact Report, highlighting the Companys sustainability, social and governance strategy, initiatives and performance. The annual report showcases how the Company continues to translate innovation into real-world impact, while embedding responsible...
Business Wire
Revvity to Hold Earnings Call on Tuesday, August 4, 2026
Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive...
Business Wire
Revvity Expands Signals AI With Anthropic Claude Integration
RVTY expands Signals AI through Anthropic's MCP ecosystem, giving scientists secure Claude access to connected R&D data and scientific context.
Zacks
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude, including Claude Science, Anthropics new AI...
Business Wire
Revvity Launches Signals AI to Advance Scientific R&D Workflows
RVTY expands AI capabilities in Signals software with Signals AI, designed to help scientists turn connected R&D data into actionable insights.
Zacks
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One platform, new capabilities from Signals AI help scientists transform connected R&D data...
Business Wire
Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.
Zacks
JPMorgan Chase & Co. Has Lowered Expectations for Revvity (NYSE:RVTY) Stock Price
JPMorgan Chase & Co. decreased their target price on shares of Revvity from $96.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday...
MarketBeat
TD Cowen Forecasts Strong Price Appreciation for Revvity (NYSE:RVTY) Stock
TD Cowen raised their target price on Revvity from $115.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
MSTR9
18
ORCL54
34
SPCX19
9Advertisement|Remove ads.